Clinical course of patients with non–small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib
Purpose: In patients with non–small cell lung cancer (NSCLC), mutations in the epidermal
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
growth factor receptor (EGFR) tyrosine kinase domain have been associated with sensitivity …
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non–small cell lung cancer patients treated with gefitinib or …
DM Jackman, BY Yeap, LV Sequist, N Lindeman… - Clinical Cancer …, 2006 - AACR
Purpose: Somatic mutations in the epidermal growth factor receptor (EGFR) have been
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
detected in patients with non–small cell lung cancer (NSCLC) and are associated with …
Epidermal growth factor receptor mutations in patients with non–small cell lung cancer
BE Johnson, PA Jänne - Cancer research, 2005 - AACR
A year has passed since mutations of the tyrosine kinase domain of the epidermal growth
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …
factor receptor (EGFR) were discovered in patients with non–small cell lung cancer …
Lung cancer with epidermal growth factor receptor exon 20 mutations is associated with poor gefitinib treatment response
JY Wu, SG Wu, CH Yang, CH Gow, YL Chang… - Clinical Cancer …, 2008 - AACR
Purpose: Clinical reports about responsiveness to gefitinib treatment in patients of non-small
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …
cell lung cancer (NSCLC) with mutations in exon 20 of epidermal growth factor receptor …
Comparison of clinical outcome of patients with non-small-cell lung cancer harbouring epidermal growth factor receptor exon 19 or exon 21 mutations
YW Won, JY Han, GK Lee, SY Park, KY Lim… - Journal of clinical …, 2011 - jcp.bmj.com
Aims Deletion of exon 19 of the epidermal growth factor receptor (EGFR) and mutation of
exon 21 are the most common EGFR mutations and predict higher response to EGFR …
exon 21 are the most common EGFR mutations and predict higher response to EGFR …
Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non–small cell …
TY Chou, CH Chiu, LH Li, CY Hsiao, CY Tzen… - Clinical cancer …, 2005 - AACR
Purpose: Mutations in epidermal growth factor receptor (EGFR) can be used to predict the
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
tumor response of patients receiving gefitinib for non–small cell lung cancer (NSCLC). We …
[HTML][HTML] Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q
S Watanabe, Y Minegishi, H Yoshizawa… - Journal of thoracic …, 2014 - Elsevier
Introduction: In non–small-cell lung cancer, an exon 19 deletion and an L858R point
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …
mutation in the epidermal growth factor receptor (EGFR) are predictors of a response to …
Screening for epidermal growth factor receptor mutations in lung cancer
Background Activating mutations in the epidermal growth factor receptor gene (EGFR)
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with …
Phase II prospective study of the efficacy of gefitinib for the treatment of stage III/IV non-small cell lung cancer with EGFR mutations, irrespective of previous …
N Sunaga, Y Tomizawa, N Yanagitani, H Iijima, K Kaira… - Lung Cancer, 2007 - Elsevier
PURPOSE: Mutations in the epidermal growth factor receptor (EGFR) gene are associated
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
with increased sensitivity of non-small cell lung cancer (NSCLC) to gefitinib, an EGFR …
Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non-small cell lung cancer
Background There are many complex and rare mutations in the epidermal growth factor
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …
receptor (EGFR) gene in non-small cell lung cancer (NSCLC) other than the two classical …